Taxotere Gets FDA Approval For Advance Head And Neck Cancer Before Chemoradiotherapy And Surgery
The US Food and Drug Administration (FDA) has approved Taxotere Injection Concentrate combined with cisplatin and 5-fluorouracil for induction therapy of locally advance squamous cell carcinoma of the head and neck before chemoradiotherapy and surgery. The Agency says the approval was based on the results of Phase II randomized, open label, international human trial, TAX 324, which demonstrated that Taxotere is safe and efficacious and appreciably improves survival.
